ScyFIX is a multi-national company based in Minneapolis, Minnesota USA, that develops eye therapy products using micro-current neuromodulation, (MCN). ScyFIX MCN is the first approved device therapy in the world for treating Retinitis Pigmentosa (RP).

ScyFIX MCN has been successful in treating other degenerative eye diseases like Macular Degeneration (ARMD), and is expected to become the standard of care for these blindness-causing diseases. ARMD is a major cause for the deterioration of eyesight in older age groups, affecting an estimated 50+ million people world-wide. It is estimated that 5% of the entire world population will develop a form of ARMD.

The ScyFIX 700 MCN device is approved for use in Europe (CE MARK). ScyFIX intends to become the world leader in the distribution of effective, non-invasive therapies for the treatment of chronic eye disorders.

Compelling Clinical Results: Retinitis Pigmentosa (RP) is a degenerative disease, and improvement in visual fields, visual acuity, or contrast sensitivity is not expected. In the RP trial, best corrected visual acuity either improved or remained stable in 94% of patients and improved in 22% of the population. Visual field improved in 63% of the patients. Patients are now using mobile phones, reading newspapers, seeing faces of family members and threading needles, none of these day to day activities were possible for these patients before using the ScyFIX MCN device. Similar compelling results have been achieved in our Dry Age-Related Macular Degeneration ("ARMD") trial as well.

Please note that ScyFIX has discontinued distributing the ScyFIX 600 product and is now only taking orders for the new ScyFIX 700 Eye Therapy System.. Distribution of the ScyFIX 600 products has been taken over by Prospectus AB based in Stockholm, Sweden (EU). For any ScyFIX 600 sales or customer service questions, please contact Prospectus, proud proprietor and distributor of all ScyFIX 600 products and accessories. The ScyFIX 600 and 700 MCN devices are offered through the on-line shop on this web site.
 
     

ScyFIX uses targeted micro-current energy to address the Dry form of Macular Degeneration (AMD) and Retinitis Pigmentosa (RP). ScyFIX has completed two human Pilot clinical trials for RP and AMD that demonstrated safety, stability and improvements in visual acuity, fields, contrast sensitivity and quality of life. Some patients are now using mobile phones, reading newspapers, seeing faces of family members and threading needles; none of these day-to-day activities were possible for these patients before using the ScyFIX.